Usmani, S. Z., Quach, H., Mateos, M., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Gavriatopoulou, M., Oriol, A., Rabin, N., Nooka, A., Qi, M., Beksac, M., Jakubowiak, A., Ding, B., Zahlten-Kumeli, A., Yusuf, A., & Dimopoulos, M. (2022). carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet oncology, 23(1), 65–76. http://access.bl.uk/ark:/81055/vdc_100148167817.0x00000f